- Conditions
- Influenza, Influenza Immunisation
- Interventions
- Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Placebo, Quadrivalent MDCK Inactivated Influenza Vaccine
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 97
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza
- Interventions
- GSK A/turkey H5N1 Influenza vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
- Conditions
- Influenza A Virus, H5N1 Subtype
- Interventions
- VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Avian Influenza, Influenza Immunisation
- Interventions
- A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
- Biological · Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
- Conditions
- Avian Influenza, Influenza
- Interventions
- AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years to 64 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 1 more
- Conditions
- Influenza
- Interventions
- Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more
- Conditions
- Bird Flu, Influenza
- Interventions
- Placebo, Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
- Other · Biological
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Kansas City, Missouri • Rochester, New York + 1 more
- Conditions
- Avian Influenza, Influenza Immunisation
- Interventions
- A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
- Biological · Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more
- Conditions
- Prophylaxis of A/H3N2v Influenza
- Interventions
- Swine Influenza
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 3 Years to 92 Years
- Enrollment
- 627 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 11
- States / cities
- Redding, California • Sacramento, California • Lenexa, Kansas + 8 more
- Conditions
- Avian Influenza, Influenza Immunisation
- Interventions
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Biological · Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
- Conditions
- Influenza (Pandemic)
- Interventions
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
- Conditions
- Influenza
- Interventions
- 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
- Biological
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 20
- States / cities
- Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
- Conditions
- Influenza, Swine-origin A/H1N1 Influenza
- Interventions
- Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 9 Years
- Enrollment
- 474 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
- Conditions
- Influenza
- Interventions
- Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 394 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 4
- States / cities
- Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
- Conditions
- Influenza (Pandemic)
- Interventions
- Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
- Conditions
- Influenza
- Interventions
- Monovalent influenza A/H7N9 virus vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Influenza A
- Interventions
- LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine, LD Bris10 M2SR H3N2 influenza vaccine, Placebo
- Biological · Other
- Lead sponsor
- FluGen Inc
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Hollywood, Florida • Lenexa, Kansas • Lexington, Kentucky + 1 more
- Conditions
- Avian Influenza
- Interventions
- MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 65 Years to 99 Years
- Enrollment
- 479 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
- Conditions
- Influenza
- Interventions
- Influenza A/H3N2 variant Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • Iowa City, Iowa • Houston, Texas + 1 more
- Conditions
- Influenza
- Interventions
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,561 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 27 more
- Conditions
- Influenza, Healthy
- Interventions
- Monovalent Influenza Vaccine, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Stockbridge, Georgia • Portland, Oregon
- Conditions
- Influenza A Virus, H5N1 Subtype
- Interventions
- H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Influenza
- Interventions
- AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
- Drug · Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- 2009 H1N1 Influenza Virus
- Interventions
- 2009 H1N1 Virus Vaccine
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York